February 22, 2024

A single dose of the typhoid conjugate vaccine Typbar TCV provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study conducted by researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health and led by in-country partners at the Malawi-Liverpool Wellcome Trust Clinical Research Programme.

Published in The Lancet, the Phase 3 clinical study involved over 28,000 healthy children in Malawi, with the TCV group showing an efficacy of 78.3 percent, preventing one case of typhoid for every 163 vaccinated children. The study supports the use of TCV in preventing typhoid, a significant health concern causing millions of illnesses and deaths annually, particularly in sub-Saharan Africa and southeast Asia.

Read more.

Depicted: A girl receives Typbar TCV vaccine for typhoid protection in a study to test the efficacy of typhoid conjugate vaccine.